Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:63c45264f9de1447ed4f46a3e4f54953]
Change in renal function in Lanreotide versus not treated patients, as assessed as slope through all eGFR measurements taken at study visits during the treatment phase of the trial (n=10), with the value obtained at month 3 as first eGFR value for slope analysis.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:63c45264f9de1447ed4f46a3e4f54953]
Change in renal function in Lanreotide versus not treated patients, as assessed as slope through all eGFR measurements taken at study visits during the treatment phase of the trial (n=10), with the value obtained at month 3 as first eGFR value for slope analysis.
Bio2RDF identifier
63c45264f9de1447ed4f46a3e4f54953
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:63c45264f9de1447ed4f46a3e4f54953
measure [clinicaltrials_vocabulary:measure]
Change in renal function
time frame [clinicaltrials_vocabulary:time-frame]
serial eGFR measurements from month 3 until end of treatment visit (month 30)
description
Change in renal function in La ...... eGFR value for slope analysis.
identifier
clinicaltrials_resource:63c45264f9de1447ed4f46a3e4f54953
title
Change in renal function seria ...... of treatment visit (month 30)
@en
type
label
Change in renal function seria ...... 45264f9de1447ed4f46a3e4f54953]
@en